UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q/A
Amendment No. 1
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2012
or
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number 0-11550
Pharmos Corporation
(Exact name of registrant as specified in its charter)
| | Nevada | | 36-3207413 | |
| | (State or other jurisdiction of incorporation or organization) | | (IRS Employer Id. No.) | |
99 Wood Avenue South, Suite 302
Iselin, NJ 08830
(Address of principal executive offices)
Registrant’s telephone number, including area code: (732) 452-9556
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x No o.
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o
Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company as defined in Rule 12b-2 of the Exchange Act.
Large accelerated filer o Non-accelerated filer o | | Accelerated filer o Smaller reporting company x | |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes x No o .
As of November 19, 2012, the Registrant had outstanding 60,170,671 shares of its $.03 par value Common Stock.
Explanatory Note
This Amendment No. 1 to Form 10-Q for the quarterly period ended September 30, 2012 of Pharmos Corporation is being filed for the sole purpose of checking the box on the cover page to indicate that Pharmos Corporation is a shell company as defined under the Securities Exchange Act and related rules and regulations.
Except as described above, the remainder of the Form 10-Q is unchanged and does not reflect events occurring after the original filing of the Form 10-Q with the Commission on November 19, 2012.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | PHARMOS CORPORATION | |
| | | | | |
| | | | | |
Date: December 10, 2012 | | | | |
| | | by: | /s/ Eric W. Fangmann | |
| | | | Eric W. Fangmann | |
| | | | Acting Principal Accounting and Financial Officer | |
